0001104659-22-080577.txt : 20220718
0001104659-22-080577.hdr.sgml : 20220718
20220718173424
ACCESSION NUMBER: 0001104659-22-080577
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220714
FILED AS OF DATE: 20220718
DATE AS OF CHANGE: 20220718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PIERCE GLENN
CENTRAL INDEX KEY: 0001256964
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37625
FILM NUMBER: 221089952
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Voyager Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640266
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-5340
MAIL ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
tm2221315-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-07-14
0
0001640266
Voyager Therapeutics, Inc.
VYGR
0001256964
PIERCE GLENN
C/O VOYAGER THERAPEUTICS, INC.,
64 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2022-07-14
4
S
0
9512
6.70
D
16788
D
Common Stock
5000
I
See Footnote
Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 13, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.74, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The securities are directly held by the Pierce Family Trust, dated October 13, 1993 (the "Pierce Family Trust"). The reporting person's immediate family members are beneficiaries of the Pierce Family Trust. The reporting person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.
/s/ Robert Hesslein, as Attorney-in-Fact for Glenn Pierce
2022-07-18